High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
This study is ongoing, but not recruiting participants.
Study NCT00080977
Information provided by National Cancer Institute (NCI)
First Received: April 7, 2004
Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
